| Title |
The Clinical and Cost Effectiveness of Inotuzumab Ozogamicin for the Treatment of Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal
|
|---|---|
| Published in |
PharmacoEconomics, March 2019
|
| DOI | 10.1007/s40273-019-00779-4 |
| Pubmed ID | |
| Authors |
Edward Cox, Ros Wade, Mathilde Peron, Kristina Charlotte Dietz, Alison Eastwood, Stephen Palmer, Susan Griffin |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 67% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 51 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 51 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 18% |
| Student > Bachelor | 7 | 14% |
| Student > Master | 5 | 10% |
| Lecturer | 3 | 6% |
| Student > Ph. D. Student | 2 | 4% |
| Other | 6 | 12% |
| Unknown | 19 | 37% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 12% |
| Nursing and Health Professions | 4 | 8% |
| Economics, Econometrics and Finance | 3 | 6% |
| Social Sciences | 3 | 6% |
| Other | 7 | 14% |
| Unknown | 20 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 April 2019.
All research outputs
#14,441,948
of 23,136,540 outputs
Outputs from PharmacoEconomics
#1,474
of 1,868 outputs
Outputs of similar age
#196,323
of 351,874 outputs
Outputs of similar age from PharmacoEconomics
#22
of 40 outputs
Altmetric has tracked 23,136,540 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,868 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one is in the 19th percentile – i.e., 19% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 351,874 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.